ESR1 and breast carcinoma: The antiproliferative effects of calcitriol and neratinib were evaluated in two HER2-positive breast cancer cell lines with distinct ER status: BT-474 (ER-positive/HER2-positive) and SK-BR-3 (ER-negative/HER2-positive) [28].